Dr. Vatakis, appointed as Medical Director, brings decades of clinical trial leadership, advancing Synbio’s credibility and the integrity of its upcoming feasibility trialNEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Synbio International Inc. (OTC: SYIN) (“Synbio” or the “Company”) is proud to announce the appointment of Dr. Nick Vatakis, MD as Medical Director. This appointment represents a major milestone in Synbio’s commitment to scientific excellence, clinical rigor, and the successful validation of its A ...

Company Performance - Boston Scientific reported Q3 sales of $5.07 billion, reflecting a year-over-year growth of 20.3% [1] - Electrophysiology sales reached $865 million in Q3, marking a significant year-over-year growth of 64.2% [2][4] - The company's cardiovascular sales totaled $3.34 billion, with a growth rate of 22.4% year-over-year [1] Product Insights - The growth in electrophysiology sales was primarily driven by the pulsed field ablation (PFA) portfolio, particularly the Farapulse system [2] - The Farapulse PFA system has been utilized in over 500,000 procedures, maintaining its position as the leading PFA technology [4] - Sales of the Farapulse system grew in double digits in the U.S. during Q3, aided by the adoption of the Opal mapping system [4] Market Outlook - Boston Scientific anticipates that PFA's global penetration will reach 50% by the end of 2025 and approximately 80% by 2028 [6] - The global electrophysiology market is projected to grow from an estimated $13 billion in 2025 to $20 billion in 2028 [6] - The company aims to continue expanding its market share in electrophysiology and maintain a strong leadership position in PFA through innovative products and resources [5]

Core Insights - Heartflow, Inc. has introduced the Heartflow PCI Navigator, an AI-driven tool designed to enhance percutaneous coronary interventions (PCI) planning by providing interventional cardiologists with a patient-specific 3D model that integrates anatomy, plaque composition, and lesion-specific physiology [1][4][11] - The PLAN CALCIUM study will be presented at the TCT 2025 conference, showcasing how AI-powered plaque analysis can influence decisions in managing highly calcified lesions during PCI [6][2] - The NAVIGATE-PCI registry will enroll approximately 2,500 patients across 30 sites to evaluate the impact of CT-guided PCI planning on physician confidence, procedural safety, and patient outcomes [8][9] Company Overview - Heartflow is a leader in AI technology for coronary artery disease (CAD), with a focus on transforming how clinicians manage care through innovative solutions [11] - The company has a robust data pipeline built from over 110 million annotated CTA images, supporting its AI-driven solutions that have been validated through over 100 studies involving more than 365,000 patients [10][11] - Heartflow's technology is backed by ACC/AHA guidelines and has been proven in real-world practice, achieving coronary CTA image acceptance rates exceeding 96% [10] Product Features - PCI Navigator integrates essential measurements, including IVUS-like and FFR-like visualizations, into a seamless web-based interface, streamlining the decision-making process in the cath lab [3][5] - The tool enhances planning by providing insights into lesion-specific physiology, stent landing zones, and optimal outcomes, thereby improving procedural efficiency and clinical confidence [7][5] Research and Development - The PLAN CALCIUM study demonstrated that AI-powered plaque analysis can significantly alter plans for calcium modification in over half of the lesions evaluated, indicating the potential for more precise coronary interventions [6][8] - The NAVIGATE-PCI registry aims to address unmet needs in PCI planning and is expected to lead to broader clinical use of PCI Navigator by 2026 [9][8]

Core Insights - Heartflow, Inc. has introduced the Heartflow PCI Navigator, an AI-driven tool designed to enhance percutaneous coronary interventions (PCI) planning by providing interventional cardiologists with a patient-specific 3D model that integrates anatomy, plaque composition, and lesion-specific physiology [1][16] - The PLAN CALCIUM study will present data at the TCT 2025 conference, demonstrating how AI-powered plaque analysis can influence decisions in managing highly calcified lesions during PCI [6][2] - The NAVIGATE-PCI registry will enroll approximately 2,500 patients across 30 sites to evaluate the impact of CT-guided PCI planning on physician confidence, procedural safety, and patient outcomes [8][9] Company Overview - Heartflow is a leader in AI technology for coronary artery disease (CAD), with a focus on transforming how clinicians manage care through innovative solutions backed by extensive clinical evidence [10][15] - The company has developed a proprietary data pipeline from over 110 million annotated CTA images, which supports its AI-driven solutions and has been validated in over 100 studies involving more than 365,000 patients [10] - Heartflow's technology is designed to provide actionable insights into plaque location, volume, and composition, facilitating early detection and accurate diagnosis of CAD [15] Product Features - The PCI Navigator integrates essential measurements, including IVUS-like and FFR-like visualizations, into a seamless web-based interface, streamlining the decision-making process in the cath lab [3][5] - The tool enhances planning by allowing interventional cardiologists to review and input data on anatomy, plaque, and lesion-specific physiology before procedures, addressing the information gap that often exists prior to PCI [4][5] - The technology aims to improve efficiency and clinical confidence for both patients and healthcare staff by consolidating necessary information into one intuitive view [5][4] Research and Development - The PLAN CALCIUM study highlights the potential of combining Heartflow Plaque Analysis with coronary CTA imaging and FFRCT analysis, showing that over half of the lesions had altered plans for calcium modification due to AI insights [6][7] - The NAVIGATE-PCI registry is set to begin in 2026, aiming to assess the broader clinical use of PCI Navigator and its impact on interventional practice and patient care [8][9]

Core Insights - Roclub has raised $11.7 million in Series A funding to support the US launch of its teleoperation platform for medical devices, addressing practitioner shortages in healthcare settings [1] - The platform allows remote management of medical equipment, with a focus on radiology, and aims to double its workforce by 2026 [2][3] Funding and Growth - The Series A funding round was led by Smedvig Ventures and YZR Capital, with participation from existing investor Speedinvest and various angel investors [1] - Roclub plans to expand its sales and customer engagement efforts alongside increasing its headcount [2] Market Demand - AAMC forecasts a potential shortfall of nearly 42,000 radiologists in the US by 2036, driving demand for remote operation solutions [3] - The company is initially targeting the remote operation of MRI and CT scanners to address this shortfall [3] Compliance and Technology - Roclub's platform is HIPAA compliant and received FDA clearance in February 2025, ensuring adherence to regulatory standards [4] - The platform enables direct video and audio communication between on-site teams, operators, and patients, enhancing operational efficiency [3] Customer Focus and Pricing Strategy - Roclub serves various healthcare sectors, including hospitals and outpatient facilities, and is developing scalable pricing models to ensure cost-effectiveness [5] - The company emphasizes measurable ROI and aims to make remote operations accessible for all healthcare providers [5] Quality Assurance - Technologists in Roclub's marketplace undergo a rigorous vetting process, including credential verification and skills assessments [6] - Continuous education and performance reviews are implemented to maintain high standards of care [6]

FendX Files Provisional Patent for Novel Antimicrobial Nanoparticle Liquid CoatingOctober 22, 2025 6:00 AM EDT | Source: FendX Technologies Inc.Vancouver, British Columbia--(Newsfile Corp. - October 22, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing their technology-based solutions to reduce the spread of harmful pathogens and support a cleaner, safer world, is pleased to announce the filing ...

Core Points - Work Medical Technology Group Ltd. experienced a significant stock surge of 50.26% in after-hours trading following a 9.19% gain during the regular session, closing at $3.92 [1][2][6] - The company announced a $1 million investment in Neologics Bioscience Inc., acquiring a 10% equity stake, which will increase Neologics' capital reserve to $10 million [2][3] - The investment agreement grants Work Medical corporate governance privileges, including board member nominations and first refusal rights on future equity sales [3][4] Stock Split and Compliance - A 1-for-100 reverse stock split was executed on October 16, reducing the number of outstanding Class A ordinary shares from approximately 96 million to 960,000 to comply with Nasdaq's minimum bid price requirements [4][5] - The reverse stock split was approved by shareholders and the board, aimed at regaining compliance with Nasdaq Marketplace Rule 5550(a)(2) [5] Stock Performance Overview - Work Medical's stock is trading near its 52-week low of $3.50, reflecting a substantial 99.35% loss over the past year, with a market capitalization of $364.46 million and an average daily trading volume of 344,000 shares [6]

Core Insights - Inspira Technologies has announced two key leadership appointments to enhance its global commercialization and governance, with Mr. Mike Hershkovitz as Vice President of Global Sales and Ms. Sivan Matza as an independent director on the Board [1][4][5] Leadership Appointments - Mr. Mike Hershkovitz brings nearly two decades of experience in U.S. and international healthcare markets, having held senior roles at Johnson & Johnson and other global med-tech organizations [3] - Ms. Sivan Matza, a director at a leading international investment management firm, has extensive experience in global finance, regulation, and accounting, which will strengthen Inspira's governance framework [2] Strategic Implications - The appointments are seen as a strategic step to enhance Inspira's capabilities and drive its commercial strategy, particularly in accelerating the adoption of its technologies in hospitals worldwide [4][5] - The company aims to align its operations with long-term industry trends, including consolidation and potential strategic partnerships, as it continues to develop advanced medical technologies [7]

Core Viewpoint - MediBeacon's Transdermal GFR System (TGFR) has received approval in China, marking a significant advancement in kidney function assessment technology, which is expected to improve patient management in chronic kidney disease (CKD) [1][4][5]. Company Overview - INNOVATE Corp. is the parent company of MediBeacon, focusing on medical technology and has a commitment to expanding access to innovative healthcare solutions globally [8]. - MediBeacon specializes in fluorescent tracer agents and their transdermal detection, holding over 60 U.S. patents and more than 245 patents worldwide [9][10]. Product Details - The TGFR system includes Lumitrace (relmapirazin) injection, MediBeacon TGFR Monitor, and MediBeacon TGFR Sensor, which together facilitate the assessment of kidney function by measuring the clearance rate of the fluorescent agent [2][12]. - Lumitrace is a non-radioactive, non-iodinated compound designed for effective kidney function measurement without interference from medications or demographic factors [11][7]. Market Opportunity - Chronic Kidney Disease (CKD) affects approximately 11% of the 1.4 billion population in China, presenting a substantial market opportunity for the TGFR system [3]. - The approval of the TGFR system in China is seen as a major step in enhancing access to kidney health management tools [5]. Clinical Implications - The TGFR system aims to provide a more accurate and immediate assessment of kidney function compared to traditional methods, which can be influenced by various non-renal factors [5][6]. - The technology is expected to transform kidney disease management by allowing real-time assessment at the point of care, potentially improving patient outcomes [7].

Core Insights - Daxor Corporation is participating in the Maxim Growth Summit, a premier small-cap investor event featuring 40 promising healthcare companies [1][7] - The event will take place on October 22-23, 2025, at the Hard Rock Hotel in New York City, with Daxor's CEO Michael Feldschuh engaging with institutional investors [1][2] Company Overview - Daxor Corporation focuses on addressing the healthcare industry's challenge of accurately measuring blood volume, which is crucial for optimal patient care and reducing hospital stays [4] - The company has developed a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic system that provides real-time, precise data, enabling clinicians to make better treatment decisions [4] - Daxor operates a state-of-the-art 20,000-square-foot manufacturing facility in the U.S. and is ISO certified, positioning it for market expansion [4]